iCoat Medical’s business idea is to develop and market medicine for successful transplants of vital organs while enabling a greater availability of organs for transplantation.
iCoat Medical’s product candidate, TUM012, has the potential to transform the transplantation market. The product is based on 25 years’ research and development in collaboration with leading academic institutes. Vast preclinical studies show that TUM012 has the potential to improve the kidney’s function following transplantation. The organisation includes surgeons and scientists with expertise in all phases of research and development as well as an experienced commercial team.
TUM012 will initially be used for kidneys but the plan is that the product will be used also in other organ transplants, such as heart. The transplantation market is large and non-cyclical, and the company estimates that more than 200 000 transplants will be carried in 2025, which is when the company’s product is expected to be ready for commercialization.